Efficacy And Safety of Levamisole in African Children With Nephrotic Syndrome: A Protocol For A Double-Blinded, Standard of Care-Controlled Randomized Trial (ESOLAC TRIAL)

Efficacy And Safety of Levamisole in African Children With Idiopathic Frequent Relapsing And Steroid Dependent Nephrotic Syndrome: A Protocol For A Double-Blinded, Standard of Care-Controlled Randomized Trial (ESOLAC TRIAL)

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

PACTR

Registry ID

PACTR202201750782433

Enrollment

Registered

2022-01-21

Start date

2022-03-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Paediatrics Kidney Disease

Interventions

Levamisole arm

Standard of care

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Children between the ages of 2 and 18 years as at the last birthday 2. Children with Steroid sensitive Nephrotic syndrome 3. Children with Idiopathic Nephrotic Syndrome 4. Children whose caregivers signed Informed consent for their participation in the study

Exclusion criteria

Exclusion criteria: 1. Children with congenital anomaly of the urogenital system 2. Children with steroid-resistant nephrotic syndrome 3. Children who are receiving other immunosuppressive drugs 4. Children with End-Stage Renal Disease. 5. Children with Co-morbid conditions OR Systemic disease

Design outcomes

Primary

Measure	Time frame
1. Number of Relapses in a period of 12 months post-randomization 2. Period of sustained remission within 12 months post-randomization.	—

Secondary

Measure	Time frame
1. Number of subjects in remission at 6, 12, and 18 months post-randomization 2. Number of solicited and unsolicited adverse events and serious events at 6, 12, and 18 months post-randomization	—

Countries

Nigeria

Contacts

Public ContactAdanze Asinobi

University College Hospital Ibadan

adasinobi@yahoo.com+2348038955880

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026